The present proposal focuses on evaluation and optimization of vaccine strategies using defined, shared melanoma peptides from the melanocytic differentiation proteins (MDPs) and cancer-testis families of proteins. In studies performed to date, we have observed immunogenicity of MDP peptides after vaccination. Challenges for optimization of peptide-based tumor vaccines include the need to optimize the magnitude of the CTL response and the need to increase the number of antigens being targeted. Successful completion of the work proposed here will contribute to optimization of peptide vaccine strategies in these areas, specifically addressing the following aims:
Aim 1 will investigate the biologic effects of a combination adjuvant on dendritic cells at the site of cutaneous vaccination and at the draining lymph nodes. This combination adjuvant includes GM-CSF and incomplete Freund's adjuvant, and the value of GMCSF in that adjuvant will specifically be evaluated.
Aim 2 will include a clinical trial that will determine whether a set of 12 peptide epitopes for melanoma-reactive CTL are immunogenic in humans when incorporated into a vaccine as free peptides and whether this 12 peptide vaccine is more effective at inducing T-cell responses than the 4 peptide vaccine.
Aim 3 will determine whether a set of 7 defined epitopes for melanoma-reactive T-helper cells are immunogenic in humans and whether they synergize to increase the magnitude of the response to CTL epitopes. Thus, the current proposal represents a continued evolution of our laboratory effort into the realm of patient-oriented research founded in basic tumor immunology. We expect that the lessons learned from optimization of peptide-based vaccine strategies will be relevant both for continued development of these approaches and also for tumor vaccines of other types. The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057653-11
Application #
6738966
Study Section
Special Emphasis Panel (ZRG1-SSS-1 (01))
Program Officer
Xie, Heng
Project Start
1992-07-01
Project End
2007-03-31
Budget Start
2004-05-11
Budget End
2005-03-31
Support Year
11
Fiscal Year
2004
Total Cost
$329,300
Indirect Cost
Name
University of Virginia
Department
Surgery
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Hu, Yinin; Kim, Helen; Blackwell, Christopher M et al. (2015) Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg 262:456-64; discussion 462-4
Ramirez, Adriana G; Wages, Nolan A; Hu, Yinin et al. (2015) Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience. Cancer Immunol Immunother 64:1531-9
Reed, Caroline M; Cresce, Nicole D; Mauldin, Ileana S et al. (2015) Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. Clin Cancer Res 21:3879-87
Hu, Yinin; Petroni, Gina R; Olson, Walter C et al. (2014) Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 63:779-86
Salerno, Elise P; Olson, Walter C; McSkimming, Chantel et al. (2014) T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer 134:563-74
Hu, Yinin; Smolkin, Mark E; White, Emily J et al. (2014) Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. Ann Surg Oncol 21:3978-84
Salerno, Elise P; Shea, Sofia M; Olson, Walter C et al. (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother 62:1149-59
Judge, Joshua M; Chianese-Bullock, Kimberly A; Schroen, Anneke T et al. (2013) Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. Clin Trials 10:143-50
Harris, Rebecca C; Chianese-Bullock, Kimberly A; Petroni, Gina R et al. (2012) The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother 35:78-88
Slingluff Jr, Craig L (2011) The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 17:343-50

Showing the most recent 10 out of 32 publications